Life-science briefing: Tuesday, March 18, 2008
TODAY’S HEADLINES:
Luminous Medical raises $24M for automated glucose monitoring (release)
Alimera Sciences gets $30M for eye-disease drug (release)
Vaccine maker LigoCyte draws $28M (release)
Heartbeat tracker CardioNet trims IPO, aims for listing today (IPOhome)
Axial Biotech takes in $6M for spinal diagnostics (release)
Insulin bioengineer enGene receives $6.4M (release)
GlucoLight raises funding for, well, glucose monitoring (release)
Germany’s InflaRx gets seed funding for sepsis work (release)
Cell imager Amnis pulls in $3.5M (VentureWire)
Korea Bone Bank gets funding for bone transplants (release)
Luminous Medical raises… Continue Reading
Life sciences briefing: Thursday, Nov. 15, 2007
Featured companies: BioVex, FullTurn Media, Humanetics, N Spine, Novitas Capital, Reliant Technologies, Symbios, Vaxart, Virtual Radiologic, Winston Laboratories, Zosano Pharma
EXPANDING ITEMS: Stay tuned.
Vaxart receives $3.3M for oral vaccines — San Francisco’s Vaxart, a biotech developing novel adenovirus-based vaccines, raised $2.7 million in a first funding round. Vaxart also received a $600,000 small-business innovation grant from the NIH to assist in developing the company’s vaccine platform.
Vaxart’s vaccine technology involves a non-replicating adenovirus engineered to produce a particular bacterial… Continue Reading
BioVex raises $22M for cancer-killing viruses
Woburn, Mass.-based BioVex, a biotech working on new ways to attack cancer and infections, raised $22 million in a fifth funding round. Triathlon Medical Ventures led the round, joined by New Science Ventures, Forbion Capital Ventures, Avalon Ventures, Credit Agricole Private Equity, GeneChem Management, Innoven Partners and Scottish Equity Partners.
BioVex is developing so-called oncolytic viruses, which are designed to infect and destroy tumor cells — long a promising but never-proven anti-cancer technique. The company put… Continue Reading
Profectus Bio pulls in $3M for antiviral drugs
Profectus BioSciences, a Baltimore, Md., developer of antiviral drugs and vaccines targeting HIV, raised $3 million in a private placement. Private investors, including Cross Atlantic Capital Partners and board member Stewart Greenebaum, contributed.
Profectus is developing ways to combine AIDS drugs with “immune modulators” that would render HIV more vulnerable to antiviral attack, and is also at work on an AIDS vaccine. The company was founded in 2003 by three eminent virologists who also co-founded the… Continue Reading